Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading STML News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.18%165.741.2%$778.89m
INCYIncyte Corporation
0.48%139.641.7%$592.23m
GILDGilead Sciences, Inc.
0.03%67.511.0%$577.68m
CELGCelgene Corporation
0.13%123.381.0%$494.27m
BIIBBiogen Inc.
-0.21%274.821.3%$452.48m
REGNRegeneron Pharmaceuticals, Inc.
2.19%373.002.1%$320.06m
KITEKite Pharma, Inc.
3.14%76.8418.8%$224.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.83%119.261.6%$202.56m
TSROTESARO, Inc.
4.15%160.0016.1%$189.31m
ESPREsperion Therapeutics, Inc.
-3.61%38.9418.7%$173.60m
ILMNIllumina, Inc.
1.72%170.583.7%$172.89m
AUPHAurinia Pharmaceuticals Inc.
-4.41%8.026.3%$150.20m
CLVSClovis Oncology, Inc.
2.61%70.3217.5%$142.57m
VRTXVertex Pharmaceuticals Incorporated
1.04%89.982.2%$135.11m
EXELExelixis, Inc.
2.95%20.917.0%$105.88m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target cancer stem cells. It currently developing two clinical stage products: SL-401 and SL-701, as well as a pipeline of preclinical candidates that include SL-801. The SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk of a variety of hematologic cancers. The SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. Stemline Therapeutics was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.